Article

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

2022-02-10

Abstract excerpt

Genetic variation of SARS-CoV-2 has resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of which Omicron is currently the predominant variant circulating worldwide. SARS-CoV-2 variants of concern or interest (VOC/VOI) have evidence of increased viral transmission, disease severity, or decreased effectiveness of vaccines and neutralizing antibodies. Remdesivir (RDV, VEKLURY ® )...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4ff98c69-601d-5c4f-8d4f-044889ac5e5b
DOI: 10.1101/2022.02.09.479840

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsDOI 10.1101/2022.02.09.479840Read

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 VariantsSemantic proximity Read

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron VariantsSemantic proximity Read

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.Semantic proximity Read

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.Semantic proximity Read

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Novel Antiviral Therapeutic Against SARS-CoV-2 and its Variants: Recent Developments and Future PerspectivesSemantic proximity Read

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialSemantic proximity Read

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read